I read in Fierce Biotech’s April 6, 2011 e-newsletter that an FDA advisory committee has recommended approval of San Diego-based Optimer Pharmaceutical’s fidaxomicin, a narrow spectrum antibacterial for the treatment of Clostridium difficile infections. C. difficile is responsible for 20% of antibiotic-associated diarrhea cases in hospitals.
Full FDA approval of a drug usually follows a positive review from its advisory committees. Approval of any new antibiotic is welcome news given the increase in resistant pathogens. However as a natural product “geek”, I was thrilled to learn that fidaxomicin is a natural product produced by fermentation of Dactylosporangium aurantiacum subspecies hamdenesis.